NICE Reverses Course on Abiraterone, Recommends Generic Version for Metastatic Prostate Cancer

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending abiraterone and its generic variants in combination with androgen deprivation therapy and prednisolone or prednisone as an option for adults with newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. The decision marks a significant reversal from NICE's 2021 guidance, which could not recommend abiraterone because it did not represent value for money for the NHS at that time.

Cost-Effectiveness Drives Policy Reversal

The availability of lower-cost generic versions prompted NICE's re-evaluation, leading to today's positive recommendation. Generic medicines are versions of brand-name drugs that have the same active ingredient, strength, and safety profile, developed after a brand-name drug's patent expires.

While generic abiraterone is already being used in some areas, its availability has varied across the NHS. NICE's positive recommendation addresses this inconsistency, expanding access to a clinically effective medicine with as many as 4,000 people now able to benefit from this additional treatment option.

Substantial NHS Savings Expected

NICE estimates the NHS could potentially save millions annually by greater use of the generic version of abiraterone rather than using enzalutamide and apalutamide, the other treatments currently recommended at this stage. These funds can be reinvested in breakthrough treatments and care improvements.

Helen Knight, Director of Medicines Evaluation at NICE, emphasized the significance of this approach: "Assessing the cost-effectiveness of generic medicines is a new departure for NICE, but one that is central to our ambition of getting the best treatments to patients quickly while ensuring the NHS gets the best value for its money."

New Whole Life-Cycle Approach

The review tested a new process as part of NICE's whole life-cycle approach to guidance development. This approach makes recommendations more responsive to changes in evidence, pricing, and clinical practice, supporting the Government's 10 Year Plan to keep NHS care up to date and cost-effective.

Knight explained: "Our whole life-cycle approach means we can respond dynamically when circumstances change, whether that's new evidence emerging or, as in this case, more affordable versions of effective treatments becoming available. This allows us to widen access where we previously couldn't recommend a treatment."

Government and Industry Support

Minister for Public Health and Prevention, Ashley Dalton, welcomed the decision: "It's brilliant that thousands of men with advanced prostate cancer will now get consistent access to a treatment that can prolong their life. By seizing the opportunity of generic medicines that deliver better value, we're making sure thousands of men with prostate cancer can now access this vital treatment - delivering better care while also driving the smarter spending our NHS desperately needs."

Mark Samuels, Chief Executive of Medicines UK (search)Search term, praised NICE's innovative approach: "This decision demonstrates how the off-patent medicines sector – which provides four in every five NHS prescriptions – plays a vital role in both improving patient access and creating financial headroom for the NHS."

Implementation Timeline

NICE expects to publish final guidance on abiraterone next month. NHS England and integrated care boards have agreed to provide funding to implement this guidance 30 days after publication, ensuring rapid access for eligible patients across the healthcare system.